Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | HRH1 | P35367 | 5/20 | 0.36 |
| ▸ | CCR3 | P51677 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019964 | 0.92 | MAPK1 (0.47) | MAPK1UTS2RHRH3HRH1CCR3 | |
| SCHEMBL3803258 | 0.89 | MAPK1 (0.38) | MAPK1UTS2RHRH3HRH1CCR3 | |
| SCHEMBL3645576 | 0.88 | UTS2R (0.40) | MAPK1UTS2RHRH3HRH1CCR3 | |
| SCHEMBL4017237 | 0.88 | HRH3 (0.44) | UTS2RHRH3HRH1CCR3 | |
| SCHEMBL4017332 | 0.87 | RECQL (0.36) | MAPK1UTS2RHRH3HRH1CCR3 | |
| SCHEMBL4017336 | 0.87 | RECQL (0.36) | MAPK1UTS2RHRH3HRH1CCR3 | |
| SCHEMBL4014069 | 0.86 | HRH3 (0.43) | MAPK1HRH3HRH1CCR3KMT2A | |
| SCHEMBL4014868 | 0.84 | KMT2A (0.46) | MAPK1HRH3HRH1CCR3KMT2A | |
| SCHEMBL4015725 | 0.83 | HRH3 (0.38) | HRH3HRH1CCR3KMT2AMEN1 | |
| SCHEMBL3814183 | 0.83 | MAPK1 (0.51) | MAPK1UTS2RHRH3HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HCAR2, HCAR1, HRH3 | MAPK1 2589/4885UTS2R 234/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.